NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
List view / Grid view
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
A new assay has been developed to screen for small molecule inhibitors of the Rh5 protein, which is essential for malaria parasite survival.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
Recent years have seen an increase in the development of biomaterial and nanoparticle-based vaccine formulations. Sushma Kumari, Sonal Asthana and Kaushik Chatterjee from the Department of Materials Engineering at the Indian Institute of Science discuss why these materials have such high potential in the fight against infectious diseases.
Six antibodies specific to the circumsporozoite protein of the malaria parasite have shown promise as therapeutic interventions, a study has shown.
In this article Maria Bernabeu, Group Leader at EMBL, Barcelona, discusses why it is important to research and develop novel therapeutics for cerebral malaria and how her research group intends to develop a 3D blood-brain barrier model for this purpose.
Researchers have shown that bicyclic azetidines, medicines used to treat malaria, can also kill the Cryptosporidium parasite in mice.
A team has discovered channels that enable the transport of lipids between the malaria parasite and red blood cells during infection.
Using a genetically attenuated parasite (GAP) with a particular deleted gene, researchers have developed a new potential malaria vaccine that arrests at the late liver stage.
A compound called tartrolon E, a byproduct of bacteria from shipworms, has been identified as researchers with the potential to fight and kill several parasites, including Cryptosporidium.
Researchers have shown that adding the RPL6 protein to malaria vaccines was successful at protecting mice against the condition.
Using an antibody to a particular malaria protein called PfGARP, researchers have developed a new strategy for designing a malaria vaccine.
A group of researchers has created a free library of 14,000 known macrolactones for other scientists to use in drug development.